Pancreatitis and pancreatic cancer in two large pooled case–control studies by Bracci, Paige M. et al.
ORIGINAL PAPER
Pancreatitis and pancreatic cancer in two large pooled
case–control studies
Paige M. Bracci Æ Furong Wang Æ Manal M. Hassan Æ
Samir Gupta Æ Donghui Li Æ Elizabeth A. Holly
Received: 12 March 2009/Accepted: 25 August 2009/Published online: 17 September 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Objective The association between duration of pancrea-
titis and pancreatic cancer has not been well characterized
in large population-based studies. We conducted detailed
analyses to determine the association between pancreatitis
onset and pancreatic cancer risk.
Methods Data from two case–control studies of pancre-
atic cancer (n = 4515) in the San Francisco Bay Area and
the M.D. Anderson Cancer Center were pooled for analysis
(1,663 cases, 2,852 frequency-matched controls). Adjusted
odds ratios (OR) were estimated using a random-effects
model.
Results In the pooled multivariable model, history of
pancreatitis was associated with a 7.2-fold increased risk
estimate for pancreatic cancer [95% conﬁdence interval
(CI): 4.0, 13]. The risk estimate was nearly 10-fold in
participantsaged\55 years (OR = 9.9, 95%CI: 3.5, 28).A
shorter temporal history of pancreatitis was more closely
associatedwithpancreaticcancerthanwasalongertemporal
history:\3 years (OR = 29, 95% CI: 12, 71), 3–10 years
(OR = 2.6, 95% CI: 1.5, 5.6), and[10 years (OR = 1.8,
95% CI: 0.7, 4.5, ptrend\0.001).
Conclusion A short temporal history of pancreatitis was
highly associated with pancreatic cancer, suggesting that
pancreatitis may be an early manifestation of pancreatic
cancer in some individuals. Pancreatic cancer should be
considered in the differential diagnosis of individuals with
an episode of pancreatitis.
Keywords Pancreatitis  Pancreatic Neoplasms 
Inﬂammation  Case–control studies  Epidemiology
Introduction
Pancreatic cancer ranks fourth in cancer-related mortality
in the United States with a 5-year survival rate of\5% and
incidence rates that are slightly higher in men than in
women [1]. The etiology and biologic mechanisms of
pancreatic cancer are not clear, but it is likely that medical
conditions, genetic, and environmental factors are involved
in tumor development as summarized in two recent reviews
[2, 3] and in other investigations [4–9]. Cigarette smoking
is one of the few established risk factors [10–12], and
preliminary data suggest that this association may be
modiﬁed for carriers of rare alleles in genes involved in the
detoxiﬁcation of polyaromatic hydrocarbons in tobacco
smoke [5].
Pancreatitis is an inﬂammatory condition of the pan-
creas, traditionally classiﬁed as acute or chronic,
although identiﬁcation of an acute episode in patients
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and acute one-time episodes may go undiagnosed
[13–16]. Alcohol is a dominant identiﬁed cause for
chronic pancreatitis, particularly among men. Although a
signiﬁcant number of individuals may have chronic
pancreatitis of idiopathic origin [14], recently published
studies suggest that overall, alcohol may account for a
smaller proportion of pancreatitis than in the earliest
studies [17, 18]. Alcohol consumption has been attributed
to pancreatitis in approximately 30–70% of men and in
0–15% of women, whereas women most commonly
have idiopathic or biliary-tract associated pancreatitis [17,
19–26].
As pancreatic cancer may obstruct pancreatic enzyme
ﬂow, pancreatitis may be a consequence of pancreatic
cancer. In studies with limited follow-up, up to 2% of
individuals with acute pancreatitis have been reported to
have pancreatic cancer [19, 20, 24–26]. However, upon
exclusion of individuals diagnosed with pancreatitis in
close proximity to pancreatic cancer, some have reported
a continued strong association between a history of pan-
creatitis and/or chronic pancreatitis and pancreatic cancer,
whereas others have not [10, 11, 27–39]. Given that
inﬂammation has been implicated in the causal pathway
of many other malignancies, possibly through increased
cell proliferation due to chronic inﬂammation in the
presence of growth factors [40–42], a causal relationship
between pancreatitis and pancreatic cancer is plausible.
Pancreatitis diagnosed in close temporal proximity to
pancreatic cancer also may represent misdiagnosis of
pancreatic cancer as pancreatitis. Research is needed to
assess misdiagnosis and the magnitude of its effect upon
risk factor analysis and to determine whether pancreatitis
is an initiating step for pancreatic cancer or a consequence
of pancreatic cancer.
Due to the aggressive nature of pancreatic cancer, a
large percentage of patients in most population-based
studies have died before they could be contacted. Very few
studies have been large enough to analyze the temporal
relationship between pancreatitis and pancreatic cancer,
and results from these few retrospective cohort studies
have been inconsistent likely due to differences in design
and analysis methods [29, 30, 33, 35].
To better elucidate the association between pancreatitis
and pancreatic cancer, data were pooled and analyzed from
a population-based case–control study conducted in the
San Francisco Bay Area and a hospital-based case–control
study conducted at the M.D. Anderson Cancer Center. We
hypothesized that pancreatitis in proximity to the diagnosis
of pancreatic cancer would be associated with higher risk
estimates for pancreatic cancer than would a diagnosis of




The San Francisco Bay Area study
Detailed methods have been published [5, 7, 9, 43–48].
Brieﬂy, a population-based case–control study was con-
ducted in the San Francisco Bay Area using rapid case
ascertainment with a goal to identify patients in the study
area within 1 month of diagnosis. Eligible patients were
diagnosed between 1995 and 1999 with incident adeno-
carcinoma of the exocrine pancreas, were between 21 and
85 years old, resided in one of the six Bay Area counties,
were alive at the time of ﬁrst attempted contact, and could
complete an interview in English. A total of 532 eligible
cases completed the interview for a 67% response rate
and 8% refusal rate [5, 7, 9, 43–48]. Patient diagnoses
were conﬁrmed by the participants’ physicians and by the
Surveillance, Epidemiology, and End Results (SEER)
abstracts that included histologic conﬁrmation of disease.
The eligibility criteria for controls were identical to those
for cases except for pancreatic cancer status. Control
participants were identiﬁed within the six San Francisco
Bay Area counties using random-digit dial and were
frequency-matched to cases by sex and by 5-year age-
groups for an approximate 1:3 case-to-control ratio.
Control recruitment for those over [65 years of age was
supplemented by random sampling of the Health Care
Finance Administration (now the Centers for Medicare &
Medicaid Services) lists for the six Bay Area counties.
A total of 1,701 eligible control participants completed
the study interview for a response rate of 67% [5, 7, 9,
43–48].
The M.D. Anderson study
A hospital-based case–control study of pancreatic cancer
was conducted between January 2001 and May 2006 at the
University of Texas M.D. Anderson Cancer Center
(MDACC). The detailed methodology has been described
previously [49, 50]. Patients with pathologically conﬁrmed
adenocarcinoma of the pancreas were identiﬁed among
patients who were evaluated and treated at the Gastroin-
testinal Cancer Clinic of the MDACC. Eligible cases were
United States’ residents, were able to communicate in
English, and had no history of other cancers including other
types of pancreatic cancer. Among 1,367 recruited patients,
236 were excluded because of missing epidemiological
information, history of cancer other than non-melanoma
skin cancer, or a pancreatic cancer diagnosis other than
primary adenocarcinoma of the exocrine pancreas. A total
of 1,131 cases with complete information were included in
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individuals who accompanied cancer patients (non-
pancreatic cancers) attending the institution’s Central
Diagnostic Radiology Clinics. Controls were not geneti-
cally related to the patients. They were the spouse, friends,
and in-laws of patients with cancers other than gastroin-
testinal malignancies, lung cancer, and head and neck
smoking-related cancers. Controls met the same criteria as
cases except that they were cancer-free and were frequency
matched to cases by age (±5 years), sex, and race/ethnic-
ity. A total of 1,115 eligible controls (84% response rate)
were included in the ﬁnal analyses.
Study conduct and data collection of both studies
In both studies, trained interviewers conducted in-person
interviews at the participants’ homes or at a convenient
location (for the San Francisco Bay Area Study) and at
M.D. Anderson Cancer Center (for the MDACC Study).
No proxy interviews were conducted at either site. Each
study used a structured questionnaire that included demo-
graphic factors, smoking, alcohol, medical, occupational,
and dietary history. Participants were asked if they ever
had been diagnosed with pancreatitis by a physician, their
age at diagnosis, the total number of episodes, whether they
had a history of chronic pancreatitis, and their age when the
last episode occurred. Because these last two pancreatitis
characteristics were not asked in the MDACC study and
numbers were too sparse for meaningful analyses in the
UCSF San Francisco Bay Area dataset, they are not
addressed in the analyses presented here.
Each study was reviewed and approved by its site-spe-
ciﬁc institutional review board, the University of California
San Francisco (UCSF) and the University of Texas
MDACC. In both studies, a written informed consent was
obtained from participants prior to interview.
For both studies, age was categorized in 5-year age-
groups for multivariable analyses. Data regarding potential
confounding factors including cigarette smoking, alcohol
consumption, diabetes mellitus, and gallbladder disease
were collected in both studies. Smokers were deﬁned as
those participants who had smoked[100 cigarettes in their
lifetime or had smoked a pipe or cigar at least once per
month for C6 months. Tobacco smoking was categorized
into ﬁve groups based on lifetime history of smoking:
never smokers; pipe and/or cigar smokers; former cigarette
smokers who had quit [15 years before diagnosis (or
interview for controls); former cigarette smokers who had
quit 1–15 years before diagnosis/interview; and current
smokers who by deﬁnition included those who quit within
1 year of diagnosis/interview. For stratiﬁed analyses, cat-
egories were dichotomized as never smokers versus ever
smokers. Alcohol consumption for those who reported ever
having consumed more than one drink per month of beer,
wine, or liquor was computed as the average amount
consumed weekly over the current and past two decades.
One drink of alcohol was deﬁned as one can, bottle, or
12 oz glass of beer, or one 4–5 oz glass of wine, or one
shot of liquor given that each contains approximately the
same amount of alcohol. Alcohol consumption was cate-
gorized as: 0 to \1 drink/week; 1–7 drinks/week; 8–14
drinks/week; 15–21 drinks/week; and [21 drinks/week.
The cut-point for the highest category was based on the top
decile of alcohol consumption among controls. Analyses
also were stratiﬁed by age \55 versus C55 years to
determine whether early pancreatic cancer onset [51]
modiﬁed the association between pancreatitis and pancre-
atic cancer and to help identify a possible subgroup for
early diagnosis.
To assess the temporal association between pancreatitis
and pancreatic cancer, we computed duration as the dif-
ference in years between age ﬁrst diagnosed with pancre-
atitis and age at pancreatic cancer diagnosis (or interview
for controls). For analyses, duration was grouped as \3,
3–10, and [10 years to distinguish pancreatitis that was
more likely to have been associated with pancreatic cancer
development from pancreatitis that was more likely due to
other factors and for comparability with other published
studies.
Statistical methods
Available data from each study were pooled using the
STATA software program(version 9; Stata Corp, College
Station, Texas). The crude associations between pancreatic
cancer status and demographic characteristics and potential
risk factors were assessed using Student’s t-test for con-
tinuous variables and the chi-square test for categorical
variables. Student’s t-test also was used to test whether age
at pancreatic cancer diagnosis was independent of history
of pancreatitis. Analyses of the pooled data were conducted
using multivariable unconditional logistic regression ﬁxed-
effects and random-effects models to compute odds ratios
(OR) as estimates of the relative risk and 95% conﬁdence
intervals [52]. Between study heterogeneity was evaluated
using the Q and I
2 statistics [53]. Variables signiﬁcant at
p\0.05 in crude analyses were considered in the multi-
variable analyses. The ﬁnal model that included age, sex,
race, smoking (not in smoking stratiﬁed analyses in
Table 2), alcohol consumption, and history of diabetes
mellitus and gallbladder disease (not in gallbladder disease
stratiﬁed analyses in Table 2) was selected based on bio-
logic plausibility and the lowest -2 log likelihood statistic.
Tests for trend for categorical variables were computed
using a likelihood ratio test based on models that included
the factor as an ordinal variable. Results were considered
Cancer Causes Control (2009) 20:1723–1731 1725
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0.05 and somewhat signiﬁcant for p-values C0.05 and
B0.10.
Results
The frequency distributions of demographic characteristics
and selected medical factors by case–control status were
similar across the study populations (Table 1). In the
pooled dataset, pancreatic cancer patients with a history of
pancreatitis were younger at diagnosis than were study
patients without pancreatitis (median age: 60 vs. 64 years,
respectively, p = 0.001). Controls in both studies also
were somewhat more likely to have higher levels of edu-
cation compared with cases.
A total of 137 cases (9%) and 28 controls (1%) reported a
history of pancreatitis (Table 2). Of these, 69% of cases and
71% of controls were former or current smokers (data not
shownintable).Historyofpancreatitiswasassociatedwitha
7.2-fold increased risk estimate for pancreatic cancer in the
pooled dataset (Table 2) and was consistent with the study-
speciﬁc estimates (UCSF: OR = 9.9, 95% CI: 4.9–20;
MDACC: OR = 5.3, 95% CI: 2.9–9.5; data not in table).
Risk estimates from multivariable stratiﬁed analyses
(Table 2) were higher in men (OR = 8.0) than in women
(OR = 6.8), in those with early-onset pancreaticcancer (age
\55 years,OR = 9.9)comparedwiththosewithlater-onset
(age C55 years, OR = 6.7), in those without gallbladder
disease (OR = 9.7) compared with those with a history of
gallbladder disease (OR = 4.1, p for interaction = 0.02)
andamongnon-smokers(OR = 11)comparedwithsmokers
Table 1 Demographic characteristics of study populations in case–control studies at the University of California San Francisco (UCSF) and the
M.D. Anderson Cancer Center (MDACC), 1999–2006
Characteristics of study populations UCSF site MDACC site







Men 291 55 883 52 651 58 682 61
Women 241 45 818 48 480 42 433 39
Age (in years)
\50 46 9 164 10 138 12 190 17
50–59 120 22 438 25 311 27 324 29
60–69 172 33 473 28 402 36 375 34
70–79 158 29 498 30 254 23 207 19
C80 36 7 128 8 26 2 19 2
Race/ethnicity
White 423 80 1,367 80 972 86 995 89
Hispanic 19 4 104 6 71 6 74 7
Black 46 9 78 5 71 6 36 3
Asian/Paciﬁc Islander 35 7 119 7 16 1 7 1
Other 9 2 33 2 1 0.1 3 0.3
Education
\High school 71 13 162 10 94 8 26 2
High school 164 31 372 22 309 27 288 26
1–4 years of college 200 38 754 44 510 45 602 54
Graduate school 97 18 413 24 218 19 199 18
History of[1 year diabetes
Yes 77 14 163 10 156 14 87 8
No 455 86 1,538 90 975 86 1,028 92
Gallbladder disease
Yes 99 19 207 12 255 23 127 11
No 432 81 1,493 88 876 77 988 89
a Numbers may not add up to the total number of participants because of missing values
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estimates were based on a small number of exposed cases,
and the associated conﬁdence intervals were wide and
overlapped for the stratiﬁed groups.
In analyses of the duration between pancreatitis and
pancreatic cancer diagnoses (Table 2), 109 of 137 cases
(80%) and 5 of 28 controls (18%) reported that their ﬁrst
episode of pancreatitis occurred\3 years before their pan-
creatic cancer diagnosis or interview (controls). ORs
decreased with increasing duration, and the risk estimate for
pancreatic cancer among those whose pancreatitis was
diagnosed \3 years before their pancreatic cancer was
substantially higher than among those whose pancreatitis
onset occurred three or more years before their pancreatic
cancer diagnosis. However, conﬁdence intervals for the
longer duration overlapped and included unity for duration
of pancreatitis of[10 years (duration:\3 years, OR = 29;
3–10 years, OR = 2.6; [10 years, OR = 1.8; trend p\
0.0001). Sparse data prevented pooled analyses of duration
stratiﬁed by sex and by early-onset (age\55 years).
Discussion
Our results demonstrate a marked strong association for
pancreatic cancer with pancreatitis diagnosed within
Table 2 Pooled adjusted odds
ratios (OR) and 95% conﬁdence
intervals (CI) for history of
pancreatitis and pancreatic
cancer: University of California




a History of pancreatitis was
missing for four cases and one
control (UCSF). Duration of
pancreatitis was missing for two
controls (MDACC)
b Odds Ratios computed using
DerSimonian & Laird random
effects model adjusted for age,
sex, race, smoking, alcohol
consumption, history of diabetes
mellitus, and gallbladder
disease. Gallbadder disease was
not included in models stratiﬁed
by gallbladder disease, and
smoking was not included in
models stratiﬁed by smoking.
p for interaction for pancreatitis
with history of gallbladder
disease was 0.02, and with
smoking was 0.14
History of pancreatitis







Yes 137/28 7.2 (4.0–13)
Men 0.4
No 864/1549 1.0
Yes 75/15 8.0 (4.1–16)
Women 0.2
No 658/1238 1.0
Yes 62/13 6.8 (3.1–15)
Age at pancreatic cancer diagnosis or at interview for controls
\55 years 0.2
No 339/718 1.0
Yes 40/6 9.9 (3.5–28)
C55 years 0.1
No 1183/2069 1.0
Yes 97/22 6.7 (2.3–20)
Duration of pancreatitis
a
\3 years 109/5 29 (12–71) 0.5
3–10 years 18/11 2.6 (1.2–5.6) 0.9
[10 years 10/10 1.8 (0.7–4.5) 0.9
p-Value for trend \0.001
No history of gallbladder diseases 0.8
No 1218/2465 1.0
Yes 88/15 9.7 (3.2–29)
History of gallbladder diseases 0.1
No 303/321 1.0
Yes 49/13 4.1 (2.0–108)
Never smokers 0.8
No 560/1185 1
Yes 43/8 11 (1.5–78)
Ever smokers 0.1
No 962/1602 1
Yes 94/20 6.8 (4.1–11)
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1233 years prior to the pancreatic cancer diagnosis. In addi-
tion, modest increased risk estimates for pancreatic cancer
that decreased over time were observed both for those with
a diagnosis of pancreatitis 3–10 years and more than
10 years before their cancer diagnosis. The observed
association may reﬂect pancreatitis as an initiator of pan-
creatic cancer and/or a consequence of pancreatic cancer.
These results require conﬁrmation and should be inter-
preted conservatively given that the CIs overlapped for the
individual categories representing the longer latencies, and
the CI for the longest duration category included unity. Our
results also support further evaluation in larger pooled
studies to determine whether other risk factors (sex, early
onset, gallbladder disease, and smoking) modify the asso-
ciation between pancreatitis and pancreatic cancer and thus
better deﬁne at-risk subgroups of patients.
Similar to our results, other studies that have examined
the temporal association between pancreatitis and pancre-
atic cancer have reported an elevated risk estimate for
pancreatic cancer diagnosed within the ﬁrst few years
following the diagnosis of pancreatitis [27, 29, 33, 35].
However, the differences in study designs and end-point
measurements and the lack of mutually exclusive groups
used in duration analyses have resulted in substantial var-
iation in reported effects [27, 29, 33, 35]. Our results are
consistent with those of a large Swedish retrospective
cohort study of patients discharged with an initial diagnosis
of pancreatitis between 1965 and 1983 [29, 33]. In
this cohort study, the standardized incidence ratio (SIR)
of pancreatic cancer decreased from 5.0 for 1–4 years
of follow-up after pancreatitis diagnosis to 1.5 for
10–24 years of follow-up [33]. Interestingly, a persistent
excess risk 10 years after pancreatitis was observed only
among patients who also had been diagnosed as alcoholics
[33]. Although our data also showed an increased risk
estimate that persisted more than 10 years after pancreatitis
diagnosis, the effect was not different from chance possibly
due to the limited number of study participants in this
category.
Our results differed from those reported for a medical
records-based case–control study conducted through the
department of Veteran Affairs (VA) in the US, although
differences in computation of duration complicated the
direct comparisons of results. Results from the VA study
showed that ORs for pancreatic cancer decreased from 2.3
for pancreatitis diagnosed C1 year before the diagnosis
of pancreatic cancer to 2.0 for pancreatitis diagnosed
7–22 years before pancreatic cancer diagnosis [27]. How-
ever, because the VA analyses did not estimate risk using
mutually exclusive categories for duration (e.g. mean
length of follow-up was 8.2 years in the group followed up
for[1 year), it is not possible from the published report to
determine whether the observed decrease in their risk
estimates is directly comparable to that observed in our
study or in the Swedish study.
In contrast to our results, a hospital-based study in Italy
reported that risk estimates for pancreatic cancer were
higher for those whose duration between pancreatitis and
pancreatic cancer diagnoses was ﬁve or more years com-
pared with those whose duration was less than 5 years [30].
The duration cut-point of 5 years used in this Italian study
prohibits a direct comparison of their results with ours and
does not provide sufﬁcient evidence to determine the effect
of duration [10 years on pancreatic cancer risk estimates
in their population. Similarly, the results from an interna-
tional clinic/hospital-based study among patients with
chronic pancreatitis estimated risk with person-years
cumulated for[2 and[5 years since pancreatitis diagnosis
[35]. Although there was some evidence among patients
with non-alcoholic chronic pancreatitis that risk may
decrease with increasing duration, long-term duration was
not assessed [35].
Multiple possible explanations for the observed associ-
ation between pancreatitis and pancreatic cancer have been
suggested including misclassiﬁcation of pancreatic cancer
as pancreatitis, mechanical effects of the tumor due to
inﬁltration of the pancreas and/or obstruction of the pan-
creatic duct, and inﬂammation. Differentiation of signs and
symptoms of pancreatic disease due to pancreatic cancer
and those due to pancreatitis can be challenging and may
have affected the speciﬁcity of pancreatitis diagnosis more
often in cases with pancreatic cancer than among controls,
leading to differential misclassiﬁcation of the pancreatitis
history. Medical record conﬁrmation was not obtained for
patients who reported a physician-diagnosed episode of
pancreatitis to support the speciﬁcity of the pancreatitis
diagnosis. The effect of misclassiﬁcation of pancreatitis
diagnosis and the possible differential in misdiagnosis
between cases and controls, if present, is unknown. If the
observed associations were due to a mechanical effect
related to underlying pancreatic cancer, pancreatitis would
be a manifestation rather than a pathogenic step in the
development of pancreatic cancer. Finally, inﬂammation
may be due to the pancreatitis and thus a pathogenic step
towards the development of pancreatic cancer, or it may be
a consequence of the pancreatic cancer itself.
The inﬂammatory-related mechanisms that may cause,
promote, or be a consequence of pancreatic cancer have not
been established. Normal inﬂammation is limited by the
release of anti-inﬂammatory cytokines. However, under
conditions of chronic inﬂammation, the factors that control
the inﬂammatory response are dysfunctional, thereby
allowing inﬂammation to continue [41]. Chronic inﬂam-
mation can promote DNA damage and cell proliferation via
release of inﬂammatory mediators such as cytokines, che-
mokines, and reactive oxygen species. The inﬂammatory
1728 Cancer Causes Control (2009) 20:1723–1731
123mediators that are commonly released during pancreatitis,
NF-KB, IL-8, COX-2, and TNF-alpha, play a role in cell
growth, proliferation, and apoptosis and also are highly
expressed in pancreatic cancer [54]. The involvement of
NF-KB is of particular interest as it is important in both
inﬂammatory and oncogenic pathways [54]. Interestingly,
in an earlier analysis of our data, we used DNA obtained
from study participants to determine genetic susceptibility
for pancreatic cancer associated with polymorphisms in
inﬂammatory-related genes, including TNF-alpha and the
chemokines, RANTES and CCR5 [55]. Our results showed
that pancreatitis modiﬁed the association between pancre-
atic cancer and polymorphisms in TNF-alpha and RANTES
such that risk estimates for pancreatic cancer were
increased among those who carried the variant alleles for
polymorphisms in these genes and also had a history of
pancreatitis. The exact signiﬁcance of these polymor-
phisms as markers of risk estimates and/or pathogenic
factors requires validation and exploration in functional
studies.
We investigated statistical interaction with other expo-
sures and factors that have been associated with pancrea-
titis and with pancreatic cancer including gallbladder
disease and smoking. Although intriguing, evidence to
support that these factors modiﬁed the association between
pancreatitis and pancreatic cancer was weak. Smoking and
gallbladder/biliary disease may promote an inﬂammatory
milieu that could contribute to pancreatitis and pancreatic
cancer [56, 57]. Interestingly, gallbladder conditions have
been associated with biliary pancreatitis which in turn has
been correlated with acute rather than chronic pancreatitis
[57]. This relationship may partly explain our observed
higher risk of pancreatic cancer among pancreatitis patients
without a history of gallbladder disease and with the lower
risk among women, who are more likely than men to have
biliary pancreatitis. However, our results suggesting that
gallbladder disease history, smoking, and sex may modify
the association between pancreatitis and risk of pancreatic
cancer should be interpreted conservatively as they were
based on a small number of exposed participants, were
imprecise and remained elevated regardless of the factor
level. The low frequency of pancreatitis limited our ability
to conduct further detailed analyses but emphasizes the
need to continue to investigate these complex associations
in larger pooled studies.
One advantage of the current combined pooled analyses
is the large sample size allowing for a detailed investiga-
tion of pancreatitis that was not possible in the individual
studies. Additionally, participants in our two studies were
interviewed in-person, thus minimizing the reporting bias
associated with proxy interviews [58, 59]. Further, we had
a very low patient-refusal rate of 8% at the population-
based UCSF site and 6% at the clinic-based MDACC site,
and the study hypotheses were unknown to the participants
and to the interviewers.
Possible limitations common to case–control studies
also should be considered when interpreting our results.
Recall bias is possible but is likely to have been diminished
by requesting that participants report ‘‘physician-diagnosed
pancreatitis’’. Similar to other population-based studies of
pancreatic cancer, a large number of patients had died prior
to initial contact due to the aggressive nature of the disease,
despite use of rapid case ascertainment methods at UCSF
and enrollment of cases at diagnosis at MDACC. Com-
parison of SEER abstract demographic data for interviewed
and non-interviewed cases identiﬁed as part of the UCSF
study showed that non-interviewed cases tended to be
slightly older, with a slightly greater proportion of women
than men, somewhat more minorities, fewer known tumor
characteristics, and a shorter survival time [46]. It is pos-
sible that cases diagnosed in proximity to their pancreatic
cancer diagnosis may have incorrectly reported their pan-
creatitis diagnosis. Although this misclassiﬁcation of pan-
creatitis may have been differential between cases and
controls and resulted in an overestimate of the association
with pancreatic cancer in the years closest to their cancer
diagnosis, the practical implications of our results remain
clinically important. Given the magnitude of the risk esti-
mate for the shortest duration and the consistently elevated
risks for longer duration, the association of long-term
pancreatitits with pancreatic cancer risk requires further
exploration.
In conclusion, results from our analyses in this large
pooled dataset provide support for the hypothesis that some
pancreatitis may be a clinical marker for early manifesta-
tion of pancreatic cancer or a pathogenic step towards the
development of pancreatic cancer. Further investigation in
larger pooled studies is required to conﬁrm our results and
to assess the joint effects with other risk factors that may
contribute to pancreatic inﬂammation such as smoking and
gallbladder disease. In addition, larger pooled analyses that
include multiple case–control studies are needed to deter-
mine whether additional characteristics of pancreatitis such
as age at pancreatitis onset, the number of episodes,
chronic or acute disease, duration by sex, and family his-
tory of pancreatitis are related to the observed association
with pancreatic cancer.
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